Mechanical Aortic Valve Replacement in Children and Adolescents After Previous Repair of Congenital Heart Disease

Abstract OBJECTIVES Some patients with complex congenital heart disease (cCHD) also require aortic valve (AoV) procedures. These cases are considered high risk but their outcome has not been well characterized. We aim to describe these scenarios in the current practice, and provide outcome data for counselling and decision-making. METHODS This was a retrospective study using the UK National Congenital Heart Disease Audit data on cCHD patients undergoing aortic valve replacement, balloon dilation (balloon aortic valvuloplasty) or surgical repair (surgical aortic valve repair) between 2000 and 2012. Coarsened exact matching was used to pair cCHD with patients undergoing AoV procedures for isolated valve disease. RESULTS A total of 201 patients with a varied spectrum of cCHD undergoing 242 procedures were included, median age 9.4 years (1 day–65 years). Procedure types were: balloon aortic valvuloplasty (n = 31, 13%), surgical aortic valve repair (n = 57, 24%) and aortic valve replacement (n = 154, 63%). Mortality at 30 days was higher in neonates (21.8% vs 5.3%, P = 0.02). Survival at 10 years was 83.1%, freedom from aortic valve replacement 83.8% and freedom from balloon aortic valvuloplasty/surgical aortic valve repair 86.3%. Neonatal age (P < 0.001), single ventricle (P = 0.08), concomitant Fontan/Glenn (P = 0.002) or aortic arch procedures (0.02) were associated with higher mortality. cCHD patients had lower survival at 30 days (93% vs 100%, P = 0.003) and at 10 years (86.4% vs 96.1%, P = 0.005) compared to matched isolated AoV disease patients. CONCLUSIONS AoV procedures in cCHD can be performed with good results outside infancy, but with higher mortality than in isolated AoV disease. Neonates and patients with single ventricle defects, especially those undergoing concomitant Fontan/Glenn, have worse outcomes.

Download Full-text

Abstract 17049: Outcomes of Bioprosthetic and Mechanical Aortic Valve Replacement in Patients With Congenital Heart Disease

Circulation ◽

10.1161/circ.142.suppl_3.17049 ◽

2020 ◽

Vol 142 (Suppl_3) ◽

Author(s):

Reilly D Hobbs ◽

Megan Schultz ◽

Catherine Wagner ◽

Richard G Ohye ◽

Edward Bove ◽

...

Keyword(s):

Congenital Heart Disease ◽

Heart Disease ◽

Aortic Valve ◽

Aortic Valve Replacement ◽

Valve Replacement ◽

Congenital Heart ◽

Valve Repair ◽

Long Term Outcomes ◽

Long Term Mortality

Introduction: Aortic valve replacement (AVR) is required in patients with congenital heart disease who are not candidates for Ross procedure or valve repair. The long-term outcomes of prosthetic AVR in patients with congenital heart disease are unknown. Methods: A single-institution, retrospective review of all patients treated with mechanical (M) and bioprosthetic (BP) AVR between 12/1985 to 2/2020 was undertaken. Results: One-hundred and ninety-three patients underwent BP (n=134) or M (n=59) AVR. Indications for AVR were insufficiency (91/193), stenosis (61/194), mixed (38/193), aneurysm (2/193), and unknown (1/193). Patients receiving M valves were more likely to be younger (18.5 years versus 29.0 years, p < 0.01) and less likely to require subsequent valve reintervention (p < 0.01). Average time to first reintervention was 76 and 71 months in the BP and M groups respectively (p = 0.785). Survival between the M and BP groups was similar (p = 0.120). Twenty-four patients who received a M valve and thirteen patients who received a BP valve died during the study period. Causes of death were cardiac (16/37), stroke (3/37), non-cardiac (4/37), and unknown (14/37). Conclusions: Long-term freedom from death or valve reintervention is poor in congenital heart disease patients requiring AVR. Survival is similar between patients treated with M and BP valves, however, BP valves more frequently required reintervention during the study period. Both BP and M valves are associated with significant long-term mortality. These results highlight the need for the development of robust aortic valve repair techniques so that AVR can be avoided.

Download Full-text

Mortality and reoperation risk after bioprosthetic aortic valve replacement in young adults with congenital heart disease

Seminars in Thoracic and Cardiovascular Surgery ◽

10.1053/j.semtcvs.2021.06.020 ◽

2021 ◽

Author(s):

Stephanie M. Fuller ◽

Michele J. Borisuk ◽

Lynn A. Sleeper ◽

Emile Bacha ◽

Luke Burchill ◽

...

Keyword(s):

Congenital Heart Disease ◽

Young Adults ◽

Heart Disease ◽

Aortic Valve ◽

Aortic Valve Replacement ◽

Valve Replacement ◽

Congenital Heart

Download Full-text

Transcatheter Aortic Valve Replacement in a Pediatric Patient With a History of Congenital Heart Disease and Recent Post-Procedure Decompensation

Journal of Cardiothoracic and Vascular Anesthesia ◽

10.1053/j.jvca.2020.05.002 ◽

2020 ◽

Vol 34 (12) ◽

pp. 3385-3389

Author(s):

Adam R. McKinney ◽

Jacob B. Meers

Keyword(s):

Congenital Heart Disease ◽

Heart Disease ◽

Aortic Valve ◽

Aortic Valve Replacement ◽

Pediatric Patient ◽

Transcatheter Aortic Valve Replacement ◽

Congenital Heart ◽

Transcatheter Aortic Valve ◽

Post Procedure ◽

History Of

Download Full-text

Pubertal status of children with congenital heart disease

Cardiology in the Young ◽

10.1017/s1047951121002651 ◽

2021 ◽

pp. 1-5

Author(s):

Zahra Ghaemmaghami ◽

Zahra Khajali ◽

Mohammad Dalili ◽

Zahra Fotovati ◽

Maryam Moradian ◽

...

Keyword(s):

Congenital Heart Disease ◽

Heart Disease ◽

Children And Adolescents ◽

Congenital Heart ◽

Normal Population ◽

Large Sample Size ◽

Pubertal Status ◽

Major Aspect ◽

Pubertal Onset ◽

Pubertal Stages

Abstract Background: CHD influences many aspects of life in affected individuals. Puberty, a major aspect of development, is a concern for patients and families. Objectives: We investigated pubertal status in children and adolescents with CHD. Methods: Patients with CHD aged 6–18 were enrolled. Cardiac diagnoses were confirmed using history, examination, and paraclinical tools including echocardiography. An endocrinologist determined pubertal stages, and the second Tanner stages for pubarche (P2), thelarche (B2), and gonadarche (G2) were considered as the pubertal onset. A study with a large sample size on pubertal onset in a normal population was used for comparison. Results: Totally, 451 patients (228 girls and 223 boys) at a median (10th–90th percentile) age of 10.79 (8.02–14.28) years for the girls and 10.72 (8.05–14.03) years for the boys were enrolled. The median (10th–90th percentile) ages at B2 and P2 in the girls with CHD were 10.77 (9.55–12.68) and 10.53 (9.39–12.28) years, respectively, which were higher than the median ages of 9.74 (8.23–11.94) and 10.49 (8.86–12.17) years in the normal girls. The median (10th–90th percentile) ages at G2 and P2 in the boys with CHD were 11.04 (8.85–13.23) and 11.88 (9.78–13.46) years, correspondingly, which were higher than the median ages of 9.01 (6.00–11.84) and 10.34 (6.84–13.10) years in the normal boys. Conclusions: Pubertal onset could be delayed in children with CHD when compared with the normal population.

Download Full-text